Nebenwirkungen · Dupixent
Dupixent 200 mg solution for injection in pre-filled syringe Dupixent 200 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 74
HOS-138413 · Präparat HOS-098186
No increase was observed in the overall incidence of infections with dupilumab compared to placebo in the safety pool for asthma clinical studies. In the 24-week safety pool, serious infections were reported in 1.0% of patients treated with dupilumab and 1.1% of patients treated with placebo. In the 52-week QUEST study, serious infections were reported in 1.3% of patients treated with dupilumab and 1.4% of patients treated with placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 94f006dbb52337a7af509c64335336d461b681b1fe9a500531e4a4744940bce4 · Zeichen 6864–7304 im Abschnitt